FasL expression on tumor-infiltrating CD8+ T cells was increased in response to immunotherapy but was not significantly different across CD8+ T cells isolated from MHC-I-positive versus MHC-I-negative tumors (Extended Data Fig. 4j–l). This evidence concerns the gene CD8A and neoplasm.